What's Happening?
Current U.S. laws do not fully protect individuals from discrimination based on their biomarker information, according to LDI Senior Fellow Emily Largent. As biomarker science advances rapidly, enabling the prediction of diseases like Alzheimer's and
Parkinson's years before symptoms appear, concerns are rising that this information could be used by insurers and employers to deny coverage or reject job applicants. Largent highlights that individuals who are biomarker-positive but asymptomatic are the least protected group, as laws like the Americans with Disabilities Act (ADA) generally presume individuals are symptomatic, and the Genetic Information Nondiscrimination Act (GINA) does not apply to biomarkers. This leaves cognitively unimpaired individuals particularly vulnerable to potential discrimination.
Why It's Important?
The inadequacy of current U.S. laws to address biomarker-based discrimination poses a significant threat to individual privacy, economic security, and equitable access to healthcare. As biomarker testing becomes more prevalent and accessible, particularly with discussions in Congress about covering Alzheimer's biomarker testing for pre-symptomatic individuals, the potential for misuse of this sensitive health information grows. Without robust legal protections, individuals might face barriers to obtaining health insurance, long-term care insurance, or employment, simply based on a predisposition to a future illness. This could deter people from seeking valuable early diagnostic information, undermining the very purpose of these scientific advancements. The lack of clear legal safeguards creates a chilling effect, potentially forcing individuals to choose between early health awareness and fundamental protections, thereby impacting public health and trust in medical innovation.
What's Next?
Policymakers are urged to consider a comprehensive approach to address the gaps in legal protection for biomarker information. Largent suggests a three-question framework: what precisely needs to be done, what laws or regulations would accomplish it, and what unintended consequences could arise. There is interest in modifying existing laws, such as GINA, to include biomarker information, but Largent cautions against hasty changes that could inadvertently weaken existing protections. Illinois has recently expanded its genetic privacy law to include biomarkers, and other states may follow suit, potentially spurring federal action. The ongoing discussion will involve engaging the public to understand their concerns and experiences with discrimination. The goal is to develop nuanced legislation that facilitates the voluntary, confidential, and nondiscriminatory use of biomarker information while safeguarding individual rights.
Beyond the Headlines
The ethical and societal implications of advanced biomarker testing extend far beyond legal protections. The ability to foresee future health conditions raises profound questions about personal identity, life planning, and the psychological burden of knowing one's predisposition to a debilitating disease. Society must grapple with how to support individuals living with such knowledge, ensuring access to counseling and support services. Furthermore, the commercialization of biomarker tests could create a two-tiered system, where access to predictive health information is dictated by socioeconomic status, exacerbating existing health disparities. The debate over biomarker discrimination also highlights the tension between individual privacy and the potential for public health benefits derived from large-scale data collection. Ultimately, the challenge is to harness the transformative potential of biomarker science to improve health outcomes while upholding fundamental human rights and fostering a just society.
